{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-23-015988","form_type":"8-K","ticker":"TWST","cik":"0001581280","company_name":"Twist Bioscience Corp","filed_at":"2023-05-05T23:59:59+00:00","discovered_at":"2026-05-14T18:03:39.506161+00:00","generated_at":"2026-06-15T16:46:54.018202+00:00","sec_items":["2.02","2.05","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Twist Bioscience Q2 revenue record $60.2M (+25% YoY); cuts 270 jobs (~25% workforce)","bullets":["Revenue $60.2M, up 25% YoY; orders $64.2M, up 17% YoY.","Net loss $59.2M ($1.04 EPS) vs $60.7M ($1.13) prior year.","Workforce reduction of ~270 employees (~25%); expects pre-tax charges $9-11M.","Withdrew prior FY2024 guidance; provided limited updated guidance focused on cost reduction.","Cash $387.7M; shipped to 2,100 customers, 152k genes."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-23-015988","json":"https://secwatch.observer/filing/0001628280-23-015988.json","markdown":"https://secwatch.observer/filing/0001628280-23-015988.md","text":"https://secwatch.observer/filing/0001628280-23-015988.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1581280/000162828023015988/0001628280-23-015988-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1581280/000162828023015988/twist-20230503.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T16:46:54.018202+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"58df8b453d3b86ec34d768a8db53dfcb1fe52d89","claim":"Twist Bioscience Corp reported fiscal second quarter ended March 31, 2023 results: revenue Total revenues for the second quarter of fiscal 2023 were $60.2 million compared to $48.1 million for the same period of, net income Net loss attributable to common stockholders for the second quarter of fiscal 2023 was $59.2 million, or $1.04 per share, EPS $1.04 per share.","evidence_excerpt":"Total revenues for the second quarter of fiscal 2023 were $60.2 million compared to $48.1 million for the same period of fiscal 2022","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1581280/000162828023015988/0001628280-23-015988-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"fiscal second quarter ended March 31, 2023"},{"label":"Revenue","value":"Total revenues for the second quarter of fiscal 2023 were $60.2 million compared to $48.1 million for the same period of"},{"label":"Net income","value":"Net loss attributable to common stockholders for the second quarter of fiscal 2023 was $59.2 million, or $1.04 per share"},{"label":"EPS","value":"$1.04 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"58df8b453d3b86ec34d768a8db53dfcb1fe52d89","claim":"Twist Bioscience Corp reported fiscal second quarter ended March 31, 2023 results: revenue Total revenues for the second quarter of fiscal 2023 were $60.2 million compared to $48.1 million for the same period of, net income Net loss attributable to common stockholders for the second quarter of fiscal 2023 was $59.2 million, or $1.04 per share, EPS $1.04 per share.","evidence_excerpt":"Net loss attributable to common stockholders for the second quarter of fiscal 2023 was $59.2 million, or $1.04 per share, compared to $60.7 million, or $1.13 per share, for the same period of fiscal 2022","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1581280/000162828023015988/0001628280-23-015988-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"fiscal second quarter ended March 31, 2023"},{"label":"Revenue","value":"Total revenues for the second quarter of fiscal 2023 were $60.2 million compared to $48.1 million for the same period of"},{"label":"Net income","value":"Net loss attributable to common stockholders for the second quarter of fiscal 2023 was $59.2 million, or $1.04 per share"},{"label":"EPS","value":"$1.04 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"afb65ba1a96136d94734359cc4fa0141f4afe73e","claim":"Twist Bioscience Corp reported fiscal 2023 results: revenue Record revenue of $60.2M in 2QFY23; up 25% over $48.1M in 2QFY22.","evidence_excerpt":"expressly set forth by specific reference in such filing. --- EX-99.1 (EX-99.1) --- Twist Bioscience Reports Fiscal Second Quarter 2023 Financial Results – Record revenue of $60.2M in 2QFY23; up 25% over $48.1M in 2QFY22 – – Orders increased to $64.2M in 2QFY23; up 17% over 2QFY22 – -- Decisive Actions to Accelerate Path to Profitability -- SOUTH SAN","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1581280/000162828023015988/0001628280-23-015988-index.htm","confidence":0.85,"family_label":"Earnings Releases","details":[{"label":"Period","value":"fiscal 2023"},{"label":"Revenue","value":"Record revenue of $60.2M in 2QFY23; up 25% over $48.1M in 2QFY22"},{"label":"Result","value":"guidance update"}],"fact_type":"earnings_release"},{"claim_id":"796581641a2006b122afed9bf13ec00e202513d2","claim":"Twist Bioscience Corp announced a restructuring with charges of between $9 and $11 million affecting worldwide (approximately 270 employees).","evidence_excerpt":"On May 3, 2023, the Company’s board of directors approved a strategic restructuring plan, which includes a reduction in force affecting approximately 270 employees worldwide, representing approximately 25% of the Company’s total workforce. The Company expects the plan to be implemented beginning in the third quarter of fiscal year 2023 and substantially completed by the end of fiscal year 2023. The Company expects to incur pre-tax charges of between $9 and $11 million, consisting of cash expenditures for employee severance and related benefit costs.","evidence_source":"SEC 8-K Item 2.05/2.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1581280/000162828023015988/0001628280-23-015988-index.htm","confidence":0.9,"family_label":"Restructurings & Charges","details":[{"label":"Type","value":"restructuring"},{"label":"Charge","value":"between $9 and $11 million"},{"label":"Affected area","value":"worldwide"},{"label":"Headcount","value":"approximately 270 employees"}],"fact_type":"restructuring_charge"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}